Form 4 for BLFS BIOLIFE SOLUTIONS INC
Accepted 2023-11-01 00:00:00 ET · period of report 2023-10-19 · accession 0001628280-23-036052 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-11-01 | 2023-10-19 | BLFS | DE GREEF RODERICK | Pres, CEO, Dir | A - Grant | — | +394.9K | 442.5K | +828% | — |
| D | 2023-11-01 | 2023-10-19 | BLFS | DE GREEF RODERICK | Pres, CEO, Dir | A - Grant | $0.00 | +394.9K | 394.9K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-10-19 | A | A | 394,856 | — | 442,539 | D | — | — | (F1) The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of their employment agreement. (F2) This reflects the total amount beneficially owned by the reporting person as of October 19, 2023. Previous Form 4's filed by the reporting person before October 19, 2023 did not reflect the acquisition of 2,421 shares. |
| 2 | Derivative | Restricted Stock Award | 2023-10-19 | A | A | 394,856 | $0.00 | 394,856 | D | $0.00 · — to — | 394,856 Common Stock | (F3) The restricted stock was granted pursuant to the Executive Employment Agreement. The restricted stock will vest in equal annual installments so long as the reporting owner remains employed by the registrant through January 1, 2027. |